16.795  0.11 (0.66%)		01-14 09:31
Open: 16.75 High: 16.795 Volume: 10,689		Pre. Close: 16.685 Low: 16.75 Market Cap: 485(M)

Short term
Mid term
Targets	6-month :	19.74	1-year :	20.28
Resists	First :	16.9	Second :	17.37
Pivot price	16.91
Supports	First :	16.14	Second :	13.43
MAs	MA(5) :	16.84	MA(20) :	16.89
	MA(100) :	16.06	MA(250) :	14.22
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	51.7	D(3) :	56.7
RSI	RSI(14): 45.3
52-week	High :	17.79	Low :	10.55

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ HQL ] has closed above bottom band by 26.3%. Bollinger Bands are 33.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	16.86 - 16.97	16.97 - 17.04
Low:	16.15 - 16.28	16.28 - 16.37
Close:	16.52 - 16.71	16.71 - 16.85

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Fri, 27 Oct 2023
Los Angeles Daily News - Tekla Capital Management LLC Announces Closing of Transaction With abrdn - FinancialContent

Fri, 27 Oct 2023
Los Angeles Daily News - Tekla Funds Approve New Investment Advisory Agreements With abrdn Inc. - FinancialContent

Wed, 13 Sep 2023
Tekla Funds Announce Adjournment of Special Meetings and Implore Shareholders to Vote Their Shares Immediately - FinancialContent

Wed, 06 Sep 2023
THQ: Still The Best Of The Tekla Suite (NYSE:THQ) - Seeking Alpha

Wed, 30 Aug 2023
Tekla Funds Announce Second Adjournment of Special Meetings and Urge Shareholder Participation to Limit the Need for Further Solicitation Efforts - FinancialContent

Tue, 15 Aug 2023
Los Angeles Daily News - Tekla Life Sciences Investors Declares Distribution - FinancialContent

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Financial Services
Industry: Asset Management
Shares Out	0 (M)
Shares Float	30 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	91 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	259.39
Profit Margin	4 %
Operating Margin	415.7 %
Return on Assets (ttm)	-346.9 %
Return on Equity (ttm)	-0.5 %
Qtrly Rev. Growth	1.94e+006 %
Gross Profit (p.s.)	-95.76
Sales Per Share	24.09
EBITDA (p.s.)	2.65753e+006
Qtrly Earnings Growth	2.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	32 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0.06
Price to Sales	0.69
Price to Cash Flow	0.7

Dividend	0
Forward Dividend	82700
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.